Citations

Showing 10 of 108104 citations.

Reimbursement of surgical procedures for benign prostatic hyperplasia: are we disincentivizing complex care?
Kellner, Daniel, Krambeck, Amy E. , Humphreys, Mitchell R. , Narang, Gopal , Humphreys, Mitchell

Mayo Clinic

Current Opinion in Urology | March 6, 2022 | Volume: 32 | Issue: 3 | Pages: 318-323

10.1097/mou.0000000000000978 | PMID 35249967 Get It

Purpose of review To provide an overview of how surgical benign prostatic hyperplasia (BPH) procedures are compensated in the United States and the implications of the current reimbursement system on the care of patients. Recent findings The resource-based relative value care system is Medicare's current reimbursement model. There is strong evidence that the current system does not adequately account for complex care. Consequently, for BPH surgical procedures, treatment options best suited for complex patients are not adequately reimbursed which may have implications on healthcare delivery and outcomes. Summary Inadequate reimbursement for certain BPH procedures may disincentivize the care of complex patients. Procedures such a holmium laser enucleation of the prostate are well suited for complex patients but have a steep learning curve. The incentive to learn and offer such procedures to complex patients may be unfairly influenced by reimbursement levels, which in the end penalizes patients and the treatments available to them.
Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder
Grant, Caroline W. , Frazee, Erin N. , Kumar, Rakesh , Skime, Michelle , Mayes, Taryn L. , Carmody, Thomas , Wang, Liewei , Weinshilboum, Richard M. , Trivedi, Madhukar H. , Croarkin, Paul E. , Athreya, Arjun P. , Frazee, Erin N , Mayes, Taryn , Weinshilboum, Richard, Bobo, William V. , Croarkin, Paul E , Kumar, Rakesh , Kaddurah‐Daouk, Rima , Biernacka, Joanna M. , Weinshilboum, Richard M.

Mayo Clinic

Journal of Personalized Medicine | March 6, 2022 | Volume: 12 | Issue: 3 | Pages: 412

10.3390/jpm12030412 | PMID 35330412 Get It

Age at depressive onset (AAO) corresponds to unique symptomatology and clinical outcomes. Integration of genome-wide association study (GWAS) results with additional “omic” measures to evaluate AAO has not been reported and may reveal novel markers of susceptibility and/or resistance to major depressive disorder (MDD). To address this gap, we integrated genomics with metabolomics using data-driven network analysis to characterize and differentiate MDD based on AAO. This study first performed two GWAS for AAO as a continuous trait in (a) 486 adults from the Pharmacogenomic Research Network-Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS), and (b) 295 adults from the Combining Medications to Enhance Depression Outcomes (CO-MED) study. Variants from top signals were integrated with 153 p180-assayed metabolites to establish multi-omics network characterizations of early (<age 18) and adult-onset depression. The most significant variant (p = 8.77 × 10−8) localized to an intron of SAMD3. In silico functional annotation of top signals (p < 1 × 10−5) demonstrated gene expression enrichment in the brain and during embryonic development. Network analysis identified differential associations between four variants (in/near INTU, FAT1, CNTN6, and TM9SF2) and plasma metabolites (phosphatidylcholines, carnitines, biogenic amines, and amino acids) in early- compared with adult-onset MDD. Multi-omics integration identified differential biosignatures of early- and adult-onset MDD. These biosignatures call for future studies to follow participants from childhood through adulthood and collect repeated -omics and neuroimaging measures to validate and deeply characterize the biomarkers of susceptibility and/or resistance to MDD development.
A Clinical Investigation on the Theragnostic Effect of MicroRNA Biomarkers for Survival Outcome in Cervical Cancer: A PRISMA-P Compliant Protocol for Systematic Review and Comprehensive Meta-Analysis
Shaw, Peter , Senthilnathan, Raghul , Sankar, Srivarshini, Ilangovan, Ilamathi, Muthukaliannan, Gothandam Kodiveri , Baxi, Siddhartha , Mani, Ravishankar Ram, Rajagopal, Mogana, Balaraman, Ashok Kumar , Suresh, Deepa, Krishnan, Sunil , Gupta, Madanmohan, Muthusamy, Thangavel, Paranjothy, Chitraabaanu , Jayaraj, Rama , Ram, M. Ravishankar , Muthukaliannan, Gothandam Kodiveri , Ram, M Ravishankar , Rajagopal, Mogana , Chinnappan, Sasikala , Krishnan, Sunil , Jayaraj, Rama , Shaw, Peter , Senthilnathan, Raghul , Thangavel, Muthusamy

Mayo Clinic

Genes | March 6, 2022 | Volume: 13 | Issue: 3 | Pages: 463

10.3390/genes13030463 | PMID 35328017 Get It

Background: The most often diagnosed malignancy in women worldwide is cancer of the cervix. It is also the most prevalent kind of gynecological cancer in women. This cancer originates in the opening of the cervix and spreads through sexual contact. Even though human papillomavirus (HPV) may not cause cancer immediately, it does develop over time as a result of the virus’s lengthy persistence to cause dysplastic changes overtime, particularly in high-risk kinds. The primary objective of this research is to see if miRNAs are dysregulated as a result of treatment resistance in cervical cancer (CC). The aim is to see if these microRNAs may be utilized as biomarkers for detecting chemoresistance in CC, particularly for clinical applications. Methods: The recommended protocol for comprehensive study and meta-analysis (PRISMA-P) standards will be utilized for the analysis and data interpretation. The bibliographic databases will be methodically searched using a combination of search keywords. Based on established inclusion and exclusion criteria, the acquired findings will be reviewed, and data retrieved from the selected scientific papers for systematic review. We will then construct a forest from the pooled Hazard ratio (HR) and 95% C.I. values, data obtained using the random-effects model. Discussion: The focus of this study is to identify the function of miRNAs as a chemoresistance regulator and determine if they have the potential scope to be considered as biomarkers for cervical cancer. Through this systematic review and meta-analysis, the goal is to collect, compare, and analyze the data pertaining to the role of miRNAs in cervical cancer, thereby, enabling us to understand the role they play in chemosensitivity.
Reply to A Letter Concerning “Aducanumab: What About the Patient?”
Petersen, Ronald C.

Mayo Clinic

Annals of Neurology | March 6, 2022 | Volume: 91 | Issue: 5 | Pages: 733-734

10.1002/ana.26344 | PMID 35249233 Get It

Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat
Rahaghi, Franck , Balasubramanian, Vijay , Chakinala, Murali M. , Eggert, Michael, Elwing, Jean , Feldman, Jeremy, King, Christopher S. , Klinger, James R. , Mathai, Stephen C. , McConnell, John W., Palevsky, Harold I. , Restrepo‐Jaramillo, Ricardo, Safdar, Zeenat , Sager, Jeffrey S., Sood, Namita , Sulica, Roxana, Hill, Nicholas S. , Elwing, Jean M , Mathai, Stephen C , Bourge, Robert C. , Burger, Charles D. , White, R. James

Mayo Clinic

Pulmonary Circulation | March 5, 2022 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/pul2.12055 | PMID 35514769 Get It

AbstractDual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with intermediate‐risk pulmonary arterial hypertension (PAH). The RESPITE and REPLACE studies suggest that switching from a PDE5i to a soluble guanylate cyclase (sGC) activator may provide clinical improvement in this situation. The optimal approach to escalation or transition of therapy in this or other scenarios is not well defined. We developed an expert consensus statement on the transition to sGC and other treatment escalations and transitions in PAH using a modified Delphi process. The Delphi process used a panel of 20 physicians with expertise in PAH. Panelists answered three questionnaires on the management of treatment escalations and transitions in PAH. The initial questionnaire included open‐ended questions. Later questionnaires consolidated the responses into statements that panelists rated on a Likert scale from −5 (strongly disagree) to +5 (strongly agree) to determine consensus. The Delphi process produced several consensus recommendations. Escalation should be considered for patients who are at high risk or not achieving treatment goals, by adding an agent from a new class, switching from oral to parenteral prostacyclins, or increasing the dose. Switching to a new class or within a class should be considered if tolerability or other considerations unrelated to efficacy are affecting adherence. Switching from a PDE5i to an SGC activator may benefit patients with intermediate risk who are not improving on their present therapy. These consensus‐based recommendations may be helpful to clinicians and beneficial for patients when evidence‐based guidance is unavailable.
Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular Senescence
Chandra, Abhishek , Lagnado, Anthony B. , Farr, Joshua N. , Schleusner, Megan , Monroe, David G. , Saul, Dominik , Passos, João F. , Khosla, Sundeep , Pignolo, Robert J. , Khosla, Sundeep , Passos, João F , Monroe, David G , Farr, Joshua N , Saul, Dominik , Chandra, Abhishek

Mayo Clinic

Journal of Bone and Mineral Research | March 5, 2022 | Volume: 37 | Issue: 5 | Pages: 997-1011

10.1002/jbmr.4537 | PMID 35247283 Get It

ABSTRACT Oxidative stress-induced reactive oxygen species, DNA damage, apoptosis, and cellular senescence have been associated with reduced osteoprogenitors in a reciprocal fashion to bone marrow adipocyte tissue (BMAT); however, a direct (causal) link between cellular senescence and BMAT is still elusive. Accumulation of senescent cells occur in naturally aged and in focally radiated bone tissue, but despite amelioration of age- and radiation-associated bone loss after senescent cell clearance, molecular events that precede BMAT accrual are largely unknown. Here we show by RNA-Sequencing data that BMAT-related genes were the most upregulated gene subset in radiated bones of C57BL/6 mice. Using focal radiation as a model to understand age-associated changes in bone, we performed a longitudinal assessment of cellular senescence and BMAT. Using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), RNA in situ hybridization of p21 transcripts and histological assessment of telomere dysfunction as a marker of senescence, we observed an increase in senescent cell burden of bone cells from day 1 postradiation, without the presence of BMAT. BMAT was significantly elevated in radiated bones at day 7, confirming the qRT-PCR data in which most BMAT-related genes were elevated by day 7, and the trend continued until day 42 postradiation. Similarly, elevation in BMAT-related genes was observed in bones of aged mice. The senolytic cocktail of Dasatinib (D) plus Quercetin (Q) (ie, D + Q), which clears senescent cells, reduced BMAT in aged and radiated bones. MicroRNAs (miRNAs or miRs) linked with senescence marker p21 were downregulated in radiated and aged bones, whereas miR-27a, a miR that is associated with increased BMAT, was elevated both in radiated and aged bones. D + Q downregulated miR-27a in radiated bones at 42 days postradiation. Overall, our study provides evidence that BMAT occurrence in oxidatively stressed bone environments, such as radiation and aging, is induced following a common pathway and is dependent on the presence of senescent cells. © 2022 American Society for Bone and Mineral Research (ASBMR). Abstract Schematic representing a senescent bone environment during aging and radiation. The schematic represents changes in an oxidatively stressed, senescent microenvironment in which mesenchymal progenitors are preferentially forming adipocytes, regulated by a common process shared between aging bone and radiation-induced bone damage, and with identical expression patterns of bone marrow adipocyte tissue (BMAT)-related genes and microRNAs (miRNAs or miRs). Increase in senescent markers p21 and p16Ink4a induce a cellular state in which production of the senescence-associated secretory phenotype (SASP) increases and influences the bone marrow environment. Secreted adipokines can promote mesenchymal stem cell (MSC) fate, switching to an adipocyte lineage. Several adipokines are also released in circulation, causing systemic effects. These changes in senescence markers and genes that regulate BMAT are in turn regulated by their corresponding miRNAs. These changes can be blocked or reversed by the clearance of senescent cells using senolytic drugs. The figure was created with BioRender.com.
Association of tumor molecular factors with in‐transit metastasis in primary cutaneous melanoma
Jakub, James W. , Weaver, Amy L. , Meves, Alexander , Jakub, James W

Mayo Clinic

International Journal of Dermatology | March 5, 2022 | Volume: 61 | Issue: 9 | Pages: 1117-1123

10.1111/ijd.16141 | PMID 35246838 Get It

AbstractBackgroundIn‐transit metastases (ITM) are a form of locoregional relapse representing intralymphatic metastatic spread and occur in approximately 4–9% of patients with melanoma >1 mm Breslow thickness. Our objective was to evaluate a combination of clinicopathologic risk factors and gene expression biomarkers predictive of ITM risk.MethodsWe used PCR to quantify gene expression in diagnostic biopsy tissue across a prospectively designed archival cohort of 854 consecutive thin and intermediate thickness primary cutaneous melanomas. The outcome of interest was ITM >90 days after a melanoma diagnosis. Cox proportional hazard models were fit to estimate each clinicopathologic and molecular characteristic’s association with the risk of ITM.ResultsThe 5‐year cumulative incidence of ITM was 3.2%. Clinical factors univariately associated with an increased risk of ITM were older age, greater Breslow thickness, greater mitotic rate, lower extremity location, ulceration, and a positive SLN biopsy. Of 108 genes tested, five were significantly upregulated and five significantly downregulated when evaluated in Cox models adjusted for age, Breslow thickness, mitotic rate, and lower extremity location. Among the upregulated genes, the strongest association was observed for interleukin‐8 (IL8).ConclusionA subset of gene expression biomarkers was identified as independently associated with the risk of ITM after adjusting for key covariates. Once sufficiently validated, our results may lead the way to regional therapy trials for a small, selected group of high‐risk patients.
Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply
Levesque, Barrett G., Feagan, Brian G. , Jucov, Alina , Bhandari, Bal Raj, Pai, Rish K. , Meadows, Kristen Taylor, Bruey, Jean‐Marie, Olson, Allan, Osterhout, Robin , Biene, Courtney Van, Ford, Julia, Aranda, Richard, Raghupathi, Kartik, Sandborn, William J. , Danese, Silvio , Sandborn, W J , Danese, Silvio , Kirby, Brian J. , Osterhout, Robin E.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 4, 2022 | Volume: 55 | Issue: 6 | Pages: 735-736

10.1111/apt.16795 | PMID 35245951 Get It

LINKED CONTENTThis article is linked to Danese et al papers. To view these articles, visit https://doi.org/10.1111/apt.16753 and https://doi.org/10.1111/apt.16761
National Network of Depression Centers' Recommendations on Harmonizing Clinical Documentation of Electroconvulsive Therapy
Zandi, Peter P. , Morreale, Michael , Reti, Irving M. , Maixner, Daniel F. , McDonald, William M. , Patel, Paresh D. , Achtyes, Eric D. , Bhati, Mahendra T. , Carr, Brent R. , Conroy, Susan K. , Cristancho, Mario A. , Dubin, Marc J. , Francis, Andrew , Glazer, Kara, Ingram, Wendy Marie , Khurshid, Khurshid, McClintock, Shawn M. , Reeves, Kevin , Rodriguez, Nelson F., Sampson, Shirlene , Seiner, Stephen J., Smetana, Roy W., Soda, Takahiro , Trapp, Nicholas T. , Wright, Jesse H. , Husain, Mustafa M. , Weiner, Richard D. , Pinjari, Omar F. , Selek, Salih , Sheline, Yvette I. , Smetana, Roy W.

Mayo Clinic

The Journal of ECT | March 4, 2022 | Volume: 38 | Issue: 3 | Pages: 159-164

10.1097/yct.0000000000000840 | PMID 35704844 Get It

Abstract Electroconvulsive therapy (ECT) is a highly therapeutic and cost-effective treatment for severe and/or treatment-resistant major depression. However, because of the varied clinical practices, there is a great deal of heterogeneity in how ECT is delivered and documented. This represents both an opportunity to study how differences in implementation influence clinical outcomes and a challenge for carrying out coordinated quality improvement and research efforts across multiple ECT centers. The National Network of Depression Centers, a consortium of 26+ US academic medical centers of excellence providing care for patients with mood disorders, formed a task group with the goals of promoting best clinical practices for the delivery of ECT and to facilitate large-scale, multisite quality improvement and research to advance more effective and safe use of this treatment modality. The National Network of Depression Centers Task Group on ECT set out to define best practices for harmonizing the clinical documentation of ECT across treatment centers to promote clinical interoperability and facilitate a nationwide collaboration that would enable multisite quality improvement and longitudinal research in real-world settings. This article reports on the work of this effort. It focuses on the use of ECT for major depressive disorder, which accounts for the majority of ECT referrals in most countries. However, most of the recommendations on clinical documentation proposed herein will be applicable to the use of ECT for any of its indications.
Betti-Number Based Machine-Learning Classifier Frame-work for Predicting the Hepatic Decompensation in Patients with Primary Sclerosing Cholangitis
Singh, Yashbir , Jons, William , Sobek, Joseph D. , Eaton, John E. , Anderies, Barrett J. , Jagtap, Jaidip , Singh, Yashbir , Erickson, Bradley J.

Mayo Clinic

2022 IEEE 12th Annual Computing and Communication Workshop and Conference (CCWC) | March 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 0159-0162

10.1109/ccwc54503.2022.9720887 Get It